Search bioRxiv⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.1101/2022.06.30.498232

Metformin protects trabecular meshwork against oxidative injury via activating integrin/ROCK signals

Xu, L.·Zhang, X.·Zhao, Y.·Cao, Y.·Liang, Y.
View original source ↗Export metadata ↓

Abstract

BackgroundThis study aimed to investigate the protective effect of metformin on the trabecular meshwork (TM) and explore its molecular mechanisms in vivo and in vitro. MethodsOcular hypertension (OHT) mouse models were induced with dexamethasone (DEX) and further treated with metformin to determine its IOP lowering effect. Cultured human TM cells (HTMC) were pre-stimulated with tert-butyl hydroperoxide (tBHP) to induce oxidative damage and then supplemented with metformin for another 24 h. The expression of fibrotic markers and integrin/ROCK signals, including -SMA, TGF-{beta}, fibronectin, F-actin, integrin beta 1, Rho-associated kinase (ROCK)1/2, AMP-activated protein kinase (AMPK), myosin light chain 1 (MLC 1), and F-actin were determined by western blotting (WB) and immunofluorescence (IF). Reactive oxygen species (ROS) content was analysed using flow cytometry (FCM). ResultsAdministration of metformin reduced the elevated IOP and alleviated the fibrotic activity of aqueous humour outflow in OHT models. Additionally, metformin rearranged the disordered cytoskeleton in the TM both in vivo and in vitro. Furthermore, metformin significantly inhibited ROS production and activated integrin/ROCK signalling induced by tBHP in HTMC. ConclusionMetformin reduced the elevated IOP in steroid-induced OHT mouse models and exerted its protective effects against oxidative injury by regulating cytoskeleton remodelling through the integrin/ROCK pathway. This study provides new insights into metformin use and preclinical evidence for the potential treatment of primary open-angle glaucoma.

Source connections

Explore related subjects

pharmacology and toxicologyPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Xu, L., Zhang, X., Zhao, Y., Cao, Y., Liang, Y.. 2022-07-03. Metformin protects trabecular meshwork against oxidative injury via activating integrin/ROCK signals. https://doi.org/10.1101/2022.06.30.498232

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Lipid-ASO therapeutics exhibit differential tissue targeted delivery upon systemic or local CNS administration

Antisense oligonucleotides (ASOs) are a powerful therapeutic modality, but their full potential is hindered by pharmacokinetic properties that affect tissue and cellular delivery. Lipid conjugation is increasingly used to modulate ASO's biodistribution and promote extrahepatic activity, yet lipid dependent effects on in vivo functional delivery, particularly in the central nervous system (CNS), remain less explored. Here, we performed a side by side in vivo comparison of cholesterol, palmitic acid (C16:0), docosanoic acid (C22:0), and eicosapentaenoic acid (C20:5) conjugated to a fully phosphorothioated 3 10 3 LNA gapmer ASO targeting the Malat1 long non coding RNA. Lipid-ASO conjugates were administered systemically or locally in the brain of mice and evaluated for tissue level and cellular level distribution by imaging, qPCR and single-cell RNA sequencing, simultaneously annotating cell origin and global transcriptional changes within the cell. Following systemic administration in mice, lipid conjugation improved overall multi organ efficacy compared to unconjugated ASO, but with pronounced tissue specific differences. Single cell sequencing of liver and heart transcriptomes revealed lipid dependent cellular uptake patterns and transcriptional responses distinct from administration of unconjugated ASO. After intracerebroventricular administration, selected fatty acid conjugates enhanced silencing in deep brain regions such as the striatum, whereas cholesterol conjugation impaired functional delivery despite increased CNS retention. Light-sheet microscopy showed restricted parenchymal penetration of cholesterol ASOs compared with broader but heterogeneous distribution of palmitic acid conjugate. Together, these findings demonstrate that lipid identity critically determines ASO efficacy, productive cellular uptake, and regional CNS engagement, emphasizing the need for context specific lipid design in ASO therapeutic development.

pharmacology and toxicology↗
bioRxiv2026

Novel Dissymmetric Ionizable Lipid-Assembled Lipid Nanoparticles for Delivery of Ferroptosis-Related siRNA in Diabetic Treatment

Small interfering RNA (siRNA) enables precise post-transcriptional gene silencing for refractory diseases, yet its clinical translation remains limited by the lack of safe and efficient delivery vectors. Inspired by the dissymmetric alkyl chain architecture of natural membrane phospholipids, we designed and synthesized 34 novel ionizable lipids with dissymmetric hydrophobic tails and formulated them into lipid nanoparticles (LNPs). Through systematic physicochemical and biological assessments, we established clear structure-activity relationships and identified two lead LNPs (O14-LNP, H18a-LNP) with superior endosomal escape capacity, enhanced in vivo gene silencing potency, and favorable biosafety relative to the clinical benchmark MC3-LNP. In both streptozotocin-induced and spontaneous db/db type 2 diabetes (T2D) mouse models, lead LNPs delivering ferroptosis-related siRNAs effectively ameliorated glucose and lipid metabolic disorders, restored islet function, and alleviated hepatic steatosis. This study not only lays a theoretical foundation for the rational design of novel ionizable lipids, but also validates the therapeutic potential of siRNA therapy targeting ferroptosis, providing a versatile delivery platform and targeted therapeutic strategy for the treatment of T2D.

pharmacology and toxicology↗
bioRxiv2024

Evaluation of common in vitro assays for the prediction of oral bioavailability and hepatic metabolic clearance in humans

IntroductionIntrinsic hepatic metabolic clearance (CLint) measured with human hepatocytes, apparent intestinal permeability (Papp) obtained using the Caco-2 model, unbound fraction in plasma (fu) and blood-to-plasma concentration ratio (Cbl/Cpl) are commonly used for predicting the hepatic clearance (CLH) and oral bioavailability (F) of drug candidates in humans. The primary objective was to select drugs whose in vitro hepatocyte CLint, Caco-2 Papp, fu and Cbl/Cpl have been measured in various laboratories and studies, and estimate correlation coefficients (R2) for predicted and observed F and log plasma CLH. Secondary aims were to estimate the laboratory/study variability and its impact on predictions and to compare results to in silico and animal model-based predictions. Materials and MethodsA literature search was done in order to find unbound hepatocyte CLint, (and corresponding predicted in vivo CLint), Caco-2 Papp, fu and Cbl/Cpl data. Compounds with multiple measurements for the four assays, without significant in vivo solubility/dissolution limitations and with known in vivo CLH and F, were selected. Min, max and mean estimates were used in the analysis. Results and DiscussionThirty-two compounds with data (in total 561 estimates) produced by 21 major pharmaceutical companies and universities met the inclusion criteria. The predicted vs observed R2 for log mean CLint, log mean CLH and mean F were 0.32, 0.08 and 0.20, respectively. Exclusion of atenolol increased the R2 for CLH to 0.20. R2-values were considerably lower than those presented in many studies, which seems to be explained by selection bias (choosing favorable reference values). There was considerable interstudy variability for measured and predicted CLint (80- and 1,476-fold mean and max differences, respectively) and measured fu (6.6- and 50-fold mean and max differences, respectively). For F, higher predictive performance was found for in silico (Q2=0.58; head-to-head) and animal in vivo models (R2=0.30). ConclusionThe combination of data from many laboratories and the use of mean values resulted in reduced selection bias and predictive accuracy. Overall, the predictive accuracy (here R2) for log CLint, log CLH and F was low to moderately low (0.08-0.32). The halved R2 compared to individual studies where high performance was demonstrated seems to be explained be selection bias (enabled by large data variability). Animal in vivo models, and in particular, in silico methodology, outperformed in vitro methodology for the prediction of F in man.

pharmacology and toxicology↗